In CRC, A-to-I editing of BLCAP by ADAR2 leads to a substitution from glutamine to proline at residue 5, accelerating degradation of BLCAP via the ubiquitination-proteasome pathway (Han et al., 2022). This evidence concerns the gene BLCAP and colorectal carcinoma.